First-in-human trial of ALS therapy ASHA-624 expected in early 2025
2024年11月20日 · What is ASHA-624? ASHA-624 was designed using Asha’s PRISM platform to “glue” the SARM1 protein, a central regulator of nerve fiber degeneration, into an inactive …
Neurosense finalizing protocol for Phase 3 ALS trial of PrimeC
2024年12月19日 · In PARADIGM (NCT05357950), a completed Phase 2b study, PrimeC was tested against a placebo, both taken as two tablets by mouth twice daily for six months, in 68 …
Choosing how to communicate about ALS — and when
2024年12月27日 · It took us more than three months to share freely that Jeff had been diagnosed with ALS. Because he had a large network of friends and colleagues around the world, we …
Leal raises $45M to advance LTX-002 to clinical trials for ALS
2024年11月6日 · The financing round, which follows an earlier $39 million investment, will help Leal move its two lead assets — LTX-002 for ALS and LTX-001 for schizophrenia — into …
Trace Neuroscience launches, aims to develop treatment for ALS
2024年11月15日 · Trace Neuroscience kicked off its operations in California with $101 million in Series A financing, which the company will use to continue developing its lead treatment …
HEALEY ALS trial to allow longer follow-up, blood cell collection
2024年12月20日 · The HEALEY ALS platform trial, which is simultaneously testing multiple potential treatments for amyotrophic lateral sclerosis (ALS), is amending its master protocol to …
ALS News Today Home | ALS News Today
3 天之前 · Zydus cleared to begin US trial of oral therapy usnoflast for ALS. Zydus Lifesciences has been cleared by the U.S. Food and Drug Administration (FDA) to initiate a Phase 2b trial …
Kadimastem, NLS merge to advance ALS therapy AstroRx, other …
2024年11月13日 · AstroRx was safe and well tolerated in the trial, with the most common side effects being mild to moderate in severity. The upcoming Phase 2a trial in the U.S. will test …
AcuraStem receives $4M grant to advance ASO treatment for ALS
2024年9月11日 · AcuraStem has received $4 million in funding from the California Institute for Regenerative Medicine (CIRM) to advance the development of AS-241, an investigational …
Qalsody halts disease progression in SOD1-ALS patients: Study
6 天之前 · Qalsody (tofersen) halted disease progression and improved functional independence and mobility in people with amyotrophic lateral sclerosis (ALS) who received the treatment in a …